Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (52)	9/30/2002 11:48:25 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

SEPR Is doing pretty good today,up 13.44% from its early L and 8.91% from Friday's close.It is now trading at its intraday H.Volume is still less than 1/2 its daily average.<g> The company recently repurchased $131 million of its 5% convertible preferred due on 2005, but Standard & Poor's said that has no impact on its current ratings of SEPR. After the repurchase, the company still has $982 million in convertible debt coming due from 2005 through 2007. As of June 30 it had $720 M in cash. According to S&P the key determinant to SPR's ratings will be the company's success over the near term on the grow in sales of Xopenex, and the FDA approvals for its late stage products, Soltara and Estorra. siliconinvestor.com It seems likely that it should test its Aug.28 H of 7.08 pretty soon. siliconinvestor.com Bernard